Havoc in oil and gas markets, the economic case for federal investment in COVID treatments, and American sentiments about the Ukraine war.
The economic case for federal investment in COVID-19 vaccines and therapeutics remains strong “While the health and economic costs of the pandemic appear to be receding, sustaining this progress will depend on the continued, broad availability of safe and effective vaccines and therapeutics.” In a new paper, Susan Athey, Rena Conti, Matthew Fiedler, Richard Frank, and Jonathan Gruber outline the importance of direct federal investment in development, manufacturing, and procurement of these life-saving remedies. Read more | Help support Brookings with a donation Brookings is committed to making its high-quality, independent policy research free to the public. Please consider making a contribution today to our Annual Fund to support our experts' work. | The conclusions and recommendations of any Brookings publication are solely those of its author(s), and do not reflect the views of the Institution, its management, or its other scholars. | |